Dr. Schilder

Russell Schilder, MD

Contact Dr. Schilder

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
  2. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
  3. Ovarian Cancer: New Targets and Future Directions
  4. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study
  5. Hereditary ovarian cancer: Not only BRCA 1 and 2 Genes
  6. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
  7. Refractory fallopian tube carcinoma - Current perspectives in pathogenesis and management
  8. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer
  9. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
  10. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
  11. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary
  12. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
  13. Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report
  14. A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
  15. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
  16. Epithelial-to-mesenchymal transition and cellular membrane receptors in ovarian cancer: Moving forward in the era of molecularly targeted therapy
  17. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
  18. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
  19. A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix
  20. Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions